What if you invested in Eli Lilly in 2000?
LLY · Healthcare · Data through 2026-06-01
If you invested $1,000 in Eli Lilly in 2000
The same $1,000 in the S&P 500 would be worth $8,517(+751.7%)
The S&P 500 returned $8,517 on the same $1,000. Eli Lilly beat the market by $27,664.
Try a different start date
Pick any month and year to see what Eli Lilly would be worth.
Compare Eli Lilly to another stock
See how Eli Lilly stacks up since 2000, head to head.
What if Eli Lilly keeps this up?
Project forward at Eli Lilly's 14.5% historical growth rate. See 5-30 year scenarios.
Growth of $1,000
Eli Lilly vs. S&P 500 vs. US Dollar, 2000 to present
Year-by-Year Returns
$1,000 invested in Eli Lilly starting January 2000
| Year | Price | Value | Annual |
|---|---|---|---|
| 2000 | $33.15 | $1,000 | - |
| 2001 | $39.61 | $1,195 | +19.5% |
| 2002 | $38.28 | $1,155 | -3.4% |
| 2003 | $31.30 | $944 | -18.2% |
| 2004 | $36.12 | $1,089 | +15.4% |
| 2005 | $29.42 | $888 | -18.5% |
| 2006 | $31.58 | $953 | +7.3% |
| 2007 | $31.09 | $938 | -1.6% |
| 2008 | $30.44 | $918 | -2.1% |
| 2009 | $22.76 | $687 | -25.2% |
| 2010 | $23.00 | $694 | +1.1% |
| 2011 | $24.00 | $724 | +4.3% |
| 2012 | $28.95 | $873 | +20.6% |
| 2013 | $40.95 | $1,235 | +41.4% |
| 2014 | $42.74 | $1,289 | +4.4% |
| 2015 | $58.87 | $1,776 | +37.7% |
| 2016 | $66.40 | $2,003 | +12.8% |
| 2017 | $66.40 | $2,003 | +0% |
| 2018 | $72.04 | $2,173 | +8.5% |
| 2019 | $108.68 | $3,278 | +50.9% |
| 2020 | $129.47 | $3,906 | +19.1% |
| 2021 | $196.69 | $5,933 | +51.9% |
| 2022 | $235.60 | $7,107 | +19.8% |
| 2023 | $334.94 | $10,103 | +42.2% |
| 2024 | $634.52 | $19,141 | +89.4% |
| 2025 | $802.35 | $24,203 | +26.4% |
| 2026 | $1,033.64 | $31,180 | +28.8% |
What this return means
A $1,000 position in Eli Lilly (LLY) opened in 2000 is worth $36,181 today. That works out to +3518.1%, about 36x the original stake, as of 2026-06-01.
That is about 14.5% a year compounded, broadly in line with long-run stock market averages. By comparison the S&P 500 returned about $8,517 on the same stake, putting Eli Lilly ahead by close to $27,664. The index compounded at about 8.4% a year over that period.
The path was not smooth. The best single year was 2024 at +89.4%, and the worst was 2009 at -25.2%. At its lowest point the position was down about 43% from an earlier high. These figures use split-adjusted closing prices and exclude dividends, taxes, trading fees, and inflation, so a real after-tax result would differ.
Treat this as history rather than advice. Past performance does not guarantee future results.
What if you invested $100 a month instead?
Most people do not drop a lump sum in on day one. They add a fixed amount every month. Putting $100 into Eli Lilly at the close of every month from January 2000 through June 2026 means 318 buys and $31,800 contributed over about 26.5 years.
$100/month, dollar-cost averaged
$811,989
+2,453.4% on $31,800 in
Same $31,800, all in at the start
$1,150,584
+3,518.2% on $31,800 in
Going all in at the start beat spreading the buys out by $338,595. That is the usual result when a stock trends up: each monthly buy pays a higher price than the last, so the average cost climbs. Averaging in also meant an average buy price of $46.97 per share across the whole stretch, so the monthly buyer never had to time a single low. Neither number counts dividends, taxes, or trading costs.
Illustrative fixed $100/month example, not a recommendation. Figures are computed from LLY split-adjusted monthly closes through June 2026. Past performance does not guarantee future results.
Eli Lilly at different times
See how the start year changes the outcome
More Healthcare investments
Compare returns across the sector
Related reading
Deep dives and analysis
Numbers worth sharing
Occasional data drops when something interesting surfaces. No schedule, just signal.
For informational and educational purposes only. Not financial advice. Past performance does not guarantee future results. All calculations are based on split-adjusted closing prices from Yahoo Finance and do not account for dividends, taxes, or trading fees. See our methodology and full disclaimer.